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Correlates and Outcomes of Posttransplant
Smoking in Solid Organ Transplant Recipients:
A Systematic Literature Review and Meta-Analysis
Nathalie Duerinckx, MSN,1,2 Hanna Burkhalter, PhD, RN,3 Sandra J. Engberg, PhD, RN,4
Monika Kirsch, PhD, RN,5 Mary-Lou Klem, PhD, MLIS,6 Susan M. Sereika, PhD, MPH,4
Paolo De Simone, MD, PhD,7 Sabina De Geest, PhD, RN, FRCN,1,8
and Fabienne Dobbels, PhD, Msc,1,8 for the B-SERIOUS consortium
Background. Despite smoking being an absolute or relative contraindication for transplantation, about 11% to 40% of all pa-
tients continue or resume smoking posttransplant. This systematic review with meta-analysis investigated the correlates and out-
comes associated with smoking after solid organ transplantation. Methods.We searched PubMed, EMBASE, CINAHL, and
PsycINFO from inception until January 2016, using state-of-the art methodology. Pooled odds ratios (ORs) with 95% confidence
intervals (CIs) were computed for correlates/outcomes investigated 5 times or more. Results. Seventy-three studies (43 in
kidney, 17 in heart, 12 in liver, 1 in lung transplantation) investigated 95 correlates and 24 outcomes, of which 6 correlates and
4 outcomes could be included in the meta-analysis. The odds of smoking posttransplant were 1.33 times higher in men (95% CI,
1.12-1.57). Older individuals were significantly less likely to smoke (OR, 0.48; 95% CI, 0.38-0.62), as were patients with a higher
body mass index (OR, 0.68; 95% CI, 0.52-0.89). Hypertension (OR, 1.16; 95% CI, 0.77-1.75), diabetes mellitus (OR, 0.52; 95%
CI, 0.15-1.78), and having a history of cardiovascular disease (OR, 0.92; 95% CI, 0.77-1.09) were not significant correlates.
Posttransplant smokers had higher odds of newly developed posttransplant cardiovascular disease (OR, 1.41; 95% CI, 1.02-
1.95), nonskin malignancies (OR, 2.58; 95% CI, 1.26-5.29), a shorter patient survival time (OR, 0.59; 95% CI, 0.44-0.79), and
higher odds of mortality (OR, 1.74; 95% CI, 1.21-2.48). Conclusions. Posttransplant smoking is associated with poor out-
comes. Our resultsmight help clinicians to understandwhich patients aremore likely to smoke posttransplant, guide interventional
approaches, and provide recommendations for future research.
(Transplantation 2016;100: 2252–2263)
Tobacco use, present in about 1 in 5 people aged 15 yearsor older in the general population,1,2 is one of the main
risk factors for a number of chronic diseases, including can-
cer, pulmonary, and cardiovascular diseases. It kills nearly
6 million people worldwide each year and continues to be
the leading global cause of preventable death.1-4
For solid organ transplant patients, smoking may be even
more harmful. Due to the need for lifelong immunosuppres-
sive medication intake, transplant recipients are already
prone to infections, cancer and cardiovascular disease, and
health risksmight be even further increasedwhen smoking. In-
deed, 2 reviews found that smoking significantly increases the
risk of renal fibrosis, malignancy, death-censored allograft
loss, and patient death in kidney transplant patients5,6; hepatic
artery thrombosis, biliary complications, and malignancy in
liver transplant patients6; and coronary atherosclerosis, malig-
nancy, renal dysfunction, all-cause, and cardiac death in heart
transplant patients.6 Corbett et al,6 however, did not conduct
a systematic review, and neither reviews used meta-analytic
techniques. They also did not make a clear distinction be-
tween pretransplant and posttransplant smoking. Moreover,
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without calculating effect sizes, it is hard to appreciate the true
association of posttransplant smoking on clinical outcomes.
In an attempt to prevent these adverse effects of post-
transplant smoking, international consensus guidelines rec-
ommend considering active tobacco smoking or tobacco
use within the last 6 months as a contraindication for lung
and heart transplantation,7-9 and strongly advise smoking
cessation before kidney and liver transplantation.10-12 How-
ever, studies show that a substantial number of transplant pa-
tients continue or resume smoking posttransplant. More
specifically, a meta-analysis of 49 studies showed 3.4 cases
of tobacco use per 100 transplant patients per year (adjusted
for follow-up duration).13 A more recent review showed that
smoking recidivism rates after transplantation vary between
11% and 40%, depending on the definition of smoking and
smoking detection methods used.6
Bearing in mind the high prevalence of posttransplant
smoking, it is of critical importance to understand which in-
dividuals are at the greatest risk for sustained or resumed
smoking, so that timely interventions can be implemented.
However, to date, few studies investigated correlates of post-
transplant smoking. In their systematic review, Dew and col-
leagues13 found that pretransplant substance use (ie, tobacco,
alcohol, and illicit drug use) was strongly correlated with
posttransplant substance use (r = 0.62; 95%confidence inter-
val [95% CI], 0.22-0.84). However, the authors did not
look at tobacco use separately, and given that the literature
search was completed in 2005, it is possible that more re-
cent evidence provides additional insights on correlates of
posttransplant smoking.
Considering these gaps, we therefore aimed to perform a
systematic literature review and meta-analysis to identify
and quantitatively synthesize available evidence on correlates
and outcomes of posttransplant smoking in adult single lung,
heart, liver, and kidney organ transplant patients.
MATERIALS AND METHODS
This systematic review and meta-analysis was conducted
in line with the methodology outlined in the Center for
Reviews and Dissemination handbook (UK),14 and followed
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guidelines for data reporting.15 Reviews on
correlates and outcomes of posttransplant alcohol use, med-
ication adherence, and physical activity were conducted in
parallel as part of the B-SERIOUS research program (Brocher
Foundation-funded grant to develop a Solid organ transplant
Endpoint model on Relationships between Influencing factors
and Outcomes of transplant Self-management behaviors).
The protocol was registered in the PROSPERO database
(registration number CRD42015003333).16
Definition of Smoking
In this review, smoking is defined as the active inhalation
of smoke of burning tobacco encased in cigarettes, pipes,
and cigars, measured by self-report or biochemical validation
of tobacco exposure, after solid organ transplantation. Thus,
this review did not include studies on electronic cigarettes,
secondhand smoke, smokeless tobacco, and smoking before
transplantation, or studies in which the distinction between
pretransplant and posttransplant smoking was not clear.
Search Strategy
We originally conducted electronic searches of PubMed,
EMBASE.COM, EBSCOhost, CINAHL, and Ovid PsycINFO,
from database inception until June 29, 2012. Searches were
updated in January 2016, covering the period of June 2012
to January 1, 2016. The search string was first developed
for PubMed in close collaboration with a health sciences li-
brarian (M.L.K.) and translated afterward for use in the
other databases. All database search strings contained both
controlled vocabulary and free text words representing the
concepts of smoking and solid organ transplantation. The
PubMed search string is shown in Table 1. The other data-
base search strings are available from the researchers upon
request. In addition to the database searches, the reference
sections of the eligible articles were searched to identify
additional studies.
TABLE 1.
Detailed search string used in the electronic database PubMed
PubMed (1323 results on January 1, 2016)
(("Heart Transplantation"(MeSH:noexp]) OR (heart transplant*(Tiab]) OR (cardiac transplant*(Tiab]) OR (heart graft*(Tiab]) OR (heart allograft*(TiabTiab]) OR (cardiac
allograft*(Tiab] OR (cardiothoracic transplant*(Tiab] OR (thoracic transplant*(Tiab] OR (Cardiac Graft* (Tiab]) OR ("Kidney Transplantation"(MeSH]) OR (kidney
transplant*(Tiab]) OR (renal transplant*(Tiab]) OR (kidney graft*(Tiab]) OR (kidney allograft*(Tiab]) OR (renal allograft*(Tiab] OR (Renal Graft* (Tiab])) OR ("Liver
Transplantation"(MeSH]) OR (liver transplant*(Tiab]) OR (hepatic transplant*(Tiab]) OR (liver graft*(Tiab]) OR (liver allograft*(Tiab]) OR (hepatic allograft*(Tiab]
OR (Hepatic Graft* (Tiab]) OR ("Lung Transplantation"(MeSH:noexp]) OR (lung transplant*(Tiab]) OR (lung graft*(Tiab]) OR (lung allograft*(Tiab]) OR (pulmonary
transplant*(Tiab] OR (Pulmonary Graft* (Tiab]) OR ("Organ Transplantation"(MeSH:noexp]) OR (solid organ*(Tiab]) OR (organ transplant*(Tiab])) AND
(((("Smoking"(MeSH]) OR (smoking(Tiab]) OR (smoker*(Tiab]) OR (exsmoker*(Tiab]) OR (ex smoker*(Tiab]) OR (cigarette*(Tiab]) OR (tobacco*(Tiab]) OR ("Smoking
Cessation"(MeSH]) OR ("Cotinine"(MeSH]) OR (cotinine(Tiab]) OR ("Tobacco Use Disorder"(MeSH]) OR ("Tobacco"(MeSH:noexp]) OR (nonsmoker*(Tiab]) OR (non
smoker*(Tiab]) OR (nonsmoking(Tiab]) OR (non smoking(Tiab]) OR ("Tobacco, Smokeless"(MeSH]) OR (smokeless tobacco(Tiab]) OR (oral tobacco(Tiab]) OR
(chew*(Tiab]) OR (snuff(Tiab]) OR ("Tobacco Use Cessation"(MeSH:noexp]) OR (moist tobacco(Tiab]) OR (snus(Tiab]))) OR ((((((((((((((((((((((((((((((((((((("Nicotine"(MeSH]))
OR ("Tobacco Use Cessation Products"(MeSH])) OR (nicotine(Tiab])) OR (nicorette(Tiab])) OR (nicotinelle(Tiab])) OR (electronic cigarette*(Tiab])) OR (cigar(Tiab] OR
cigars(Tiab])) OR ("Cannabis"(MeSH])) OR (cannabis(Tiab])) OR (marijuana(Tiab])) OR (marihuana(Tiab])) OR (ganja(Tiab])) OR (hashish(Tiab])) OR (bhang(Tiab])) OR
("Marijuana Smoking"(MeSH])) OR ("Marijuana Abuse"(MeSH])) OR (hookah(Tiab])) OR (narghile(Tiab])) OR (bidi(Tiab] OR bidis(Tiab])) OR (shisha(Tiab])) OR
(waterpipe*(Tiab])) OR (water pipe*(Tiab])) OR (chillum(Tiab])) OR (sheisha(Tiab])) OR (qalyan(Tiab])) OR ("Tobacco Smoke Pollution"(MeSH])) OR (passive smok*(Tiab]))
OR (secondhand smok*(Tiab])) OR (second hand smok*(Tiab])) OR (involuntary smok*(Tiab])) OR (goza(Tiab])) OR (argileh(Tiab])) OR (narkeela(Tiab])) OR (hubble bub-
ble(Tiab])) OR (hooka(Tiab])) OR (hukka(Tiab])))
MeSH, Medical Subject Heading; Tiab, Title/Abstract.
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Inclusion and Exclusion Criteria
To be included, reported studies had to meet all of the fol-
lowing criteria: (1) original or primary quantitative research
or mixed methods research; (2) conducted in adult single
lung, heart, liver, or kidney transplant patients; (3) mea-
sured posttransplant smoking; (4) assessed the association
between posttransplant smoking and correlates and/or
clinical, economic, and quality of life outcomes; (5) in-
cluded information needed to allow effect size calculation
(at a minimum, the sample size, information on the direction
of the association, and a P value less or more than a specified
value [eg, P < 0.05; P > 0.01]); (6) reported in English, Dutch,
German, French, Portuguese, Italian, or Spanish; and (7) full
text available.
The following papers were excluded: (1) papers that did
not report results from an original quantitative or mixed
method study (eg, results from qualitative research only, re-
view, editorial, dissertation, book chapter, case studies, or
case series with no descriptive data), (2) abstracts not accom-
panied by a full paper, (3) studies on children or adolescents
aged 18 years or younger, (3) studies on combined organ
transplant populations (eg, liver-kidney), (4) studies on other
types of tissue or organ transplantation (eg, stem cell or pan-
creas transplantation), and (5) quantitative studies focusing
on a different topic or not addressing correlates or outcomes
of posttransplant smoking.
Study Selection
First, pairs of researchers (N.D., H.B., M.K., and S.E.) in-
dependently screened all titles and abstracts against the inclu-
sion and exclusion criteria to identify potentially relevant
papers. Second, the full article of potentially relevant ab-
stracts was obtained and evaluated for eligibility by the same
researchers. Comparisons were made afterward and any scor-
ing discrepancies were resolved. A third researcher (F.D.) was
involved in cases of disagreement. In case ofmultiple publica-
tions reporting similar results from the same patient samples
(ie, companion papers), data were extracted from the most
recent publication only or from the article with the largest
sample size or most complete data set.
Data Extraction
We extracted the following data from each study using a
data extraction form developed for the purpose of this re-
view: first author name, journal, publication year and language,
continent and country where the study was conducted, funding
source, study design, sample characteristics (eg, sample design,
sample size, sample size calculation, transplant population, age,
sex, race, time posttransplant), details on the posttransplant
smoking behavior (eg, definition of smoking, types of smoking,
smoking measurement, quantification of smoking, and prev-
alence of posttransplant smoking), and whether researchers
used a theoretical or conceptual framework. Further, we tab-
ulated all the correlates and outcomes studied. The correlates
were classified according to the World Health Organization
taxonomy originally designed for medication adherence into
the following 5 dimensions: socioeconomic-, patient-, condition-,
treatment-, and healthcare team- and system-related factors.17
Outcomes were divided into clinical, economic, and quality
of life outcomes. Outcomes were defined as conditions that
are not yet present at time of transplantation, but develop
posttransplant. If conditions (eg, hypertension, cardiovascular
disease) were present before or at the time of transplantation,
they were classified as condition-related factors. For both
correlates and outcomes, we extracted the descriptive re-
sults, inferential analysis results and effect sizes if available
in the article.
Data were extracted independently by 2 researchers and
compared afterward. Inconsistencies were resolved by con-
sensus or consultation with a third researcher.
Quality Assessment
Two researchers rated each study independently on 14
components of methodological quality, using an adapted ver-
sion of a checklist developed by Harlein and colleagues.18,19
The quality criteria were related to the definitions used, re-
search design, sampling strategies, sample sizes, psychomet-
ric properties of the instruments, methods for data analysis,
completeness of data reporting, and reproducibility of the
study. To determinewhether the sample sizewas appropriate,
we checked whether there was an a priori sample size justifi-
cation. If not, we checked if there were at least 104 + m sub-
jects (where m is the number of independent variables) for
testing individual predictors or 50 + 8 m subjects for testing
multivariate analysis.20 In the case of disagreement, articles
were reviewed again and discussed until consensus was
reached. Because not all quality criteria were applicable to
all studies, we did not calculate total scores.
Data Analysis
Descriptive statistics were calculated to describe the char-
acteristics of the studies included. Effect sizes, expressed as
odds ratios (ORs) with 95% CIs, were extracted or calcu-
lated for correlates or outcomes investigated by a sufficient
numbers of studies (ie, ≥ 5). The OR was calculated directly
when group frequencies were reported. If studies reported 3
groups of smokers (ie, nonsmokers, past smokers, and cur-
rent smokers), nonsmokers and past smokers were combined
and compared with the current smokers, because we were
particularly interested in correlates and outcomes of active
posttransplant smoking. If only medians and interquartile
ranges were reported for each of the 3 groups, with 1 single
P value comparing the 3 groups simultaneously, noOR could
be calculated. If frequencies were not reported, the OR was
calculated indirectly using the descriptive or inferential statis-
tics reported. The web-based Practical Meta-Analysis Effect
Size Calculator was used to facilitate the calculation of
ORs.21 For the purpose of this meta-analysis, posttransplant
smokers were always included in the exposed group irrespec-
tive of duration or intensity of smoking posttransplant.
A random-effects model was used to calculate the sum-
mary OR across all contributing studies using the Compre-
hensive Meta-Analysis software (version 2.2, Biostat, Inc.,
Englewood, NJ).22 Random effects models account for any
observed heterogeneity regardless of whether the heterogene-
ity is statistically significant. For each statistically significant
average effect size, we calculated the classic failsafe N to esti-
mate the impact of publication bias. The most commonly
suspected publication bias is the tendency to only publish
studies with statistically significant results. The classic failsafe
N is the number of nonsignificant studies that would be
needed to make the combined effect size statistically insignif-
icant. We also calculated Cochran Q to determine whether
there was significant variability in effect sizes across studies.
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Given that the Q test, however, has limited power to detect
significant heterogeneity when the number of studies is small,
we also calculated indices summarizing heterogeneity, that is,
the τ2 (the variance of the true effect sizes) and I2 (the percent-
age of variations across studies due to heterogeneity rather
than chance).23
Correlates and outcomes studied less than 5 timeswere not
included in the meta-analysis and are summarized in bar
charts. The bar charts represent the number of papers that
studied a specific factor and whether the association between
the correlate/outcome and posttransplant smoking was sig-
nificant or nonsignificant.
RESULTS
Study Selection
Figure 1 shows the number of papers excluded at each
stage of the review. Starting from 4223 references, 73 papers
met the inclusion criteria.
Study Characteristics
Table 2 summarizes the study characteristics. Among
the 73 included papers, 43 studies focused on kidney, 17 on
heart, 12 on liver, and 1 on lung transplant patients. Most
studies were conducted in Europe (n = 48, 65.8%) and used
a prospective observational design (n = 26, 35.6%). The me-
dian sample size was 185 (range, 34-41705). The mean age
of participants was 48.5 years (range, 13-84 years).
There was a wide variation in reported rates of post-
transplant smoking (range, 1.0-73.0%; mean, 24.27%). In
terms of assessment, only 40 studies (54.8%) reported how
they measured smoking, with patient self-report being the
most common measurement method (n = 26, ie, 35.6%)
and only 6 studies using biomarkers of tobacco exposure
(eg, serum and urinary cotinine levels, carboxyhemoglobin
levels).24-27 Only 22 studies (28.8%) mentioned smoking
type, of which the majority (n = 21, 95.5%) referred to ciga-
rettes. Most studies looked at sustained smoking or relapse,
whereas only 1 study investigated new-onset posttransplant
smoking exclusively (excluding patients with a history of
smoking pretransplant).28
Quality Assessment
Figure 2 shows the results of the quality assessment. The
majority of studies used appropriate sample sizes (n = 45,
61.6% for univariable tests, n = 35, 47.9% for multivariable
tests) and data analysis methods (n = 60, 82.2%). Only 28
studies (38.4%) used a clear definition for smoking; 12 stud-
ies (16.4%) defined the correlates investigated; 26 studies
(35.6%) used a prospective design; 13 studies (17.8%) de-
scribed their data collection procedures in a comprehensive
way; and, respectively, 3 (4.1%) and 8 studies (11.0%) fully
or partially reported on the psychometric properties of the in-
struments used. Moreover, none of the studies described the
methods in ways that they could be replicated accurately.
Correlates of Posttransplant Smoking
Included studies identified 95 correlates of posttransplant
smoking, of which 89 were studied less than 5 times (pre-
sented as bar charts, see Figures 3-6), consisting of 8
FIGURE 1. Flow chart of study selection process (adapted from Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow-
chart guidelines).
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socioeconomic-related factors (Figure 3), 16 patient-related
factors (Figure 4), 49 condition-related factors (Figure 5),
and 16 treatment-related factors (Figure 6). None of the stud-
ies examined the relationship between posttransplant smoking
and healthcare team/system-related factors.
Average effect size estimates could be calculated for 6 cor-
relates (Table 3, Figure 7). The odds of posttransplant smoking
was 1.33 times higher in men than in women (95% CI, 1.12-
1.57; P = 0.001). Older individuals had significantly lower
odds than those who were younger. For each year increase
in age, the odds of smoking decreased by 0.48 (95% CI,
0.38-0.62; P < 0.001). For body mass index (BMI), evidence
suggests that for every 1 unit increase (kg/m2) in BMI, the
odds of smoking decreased by 0.68 (95% CI, 0.52-0.89;
P = 0.006). Pooling data from 7 studies, it was shown that
having hypertension or being treated with antihypertensive
drugs was not significantly associated with posttransplant
smoking (OR, 1.16; 95% CI, 0.77-1.75; P = 0.467). The
same applied for diabetes mellitus (already present at time
of transplantation or unclear if newly developed) (OR,
0.52; 95% CI, 0.15-1.78; P = 0.301) (based on 7 studies),
and a history of cardiovascular disease (OR, 0.92; 95% CI,
0.77-1.09; P = 0.308) (based on 5 studies).
Examination of the variability in study effect sizes for corre-
lates reported in terms of I2 in Table 3 indicate low heterogene-
ity for sex (I2 = 24.42%) and history of cardiovascular disease
(I2 = 0%); moderate heterogeneity for BMI (I2 = 50.12%); and
high levels of heterogeneity for age (I2 = 71.55%), hyperten-
sion (I2 = 72.94%), and diabetes (I2 = 97.56%). In particular,
the directions of the ORs for hypertension and diabetes were
inconsistent across the studies (ie, ORs >1 and <1).
Outcomes of Posttransplant Smoking
Included studies examined 24 outcomes of posttrans-
plant smoking, of which 20 were studied less than 5 times
(Figure 8). There was only 1 study investigating the associa-
tion with health-related quality of life and no studies investi-
gating economic outcomes.
TABLE 2.
Characteristics of included studies (n = 73)
Type of organ transplant
Characteristics Total (n = 73) Kidney (n = 43) Heart (n = 17) Liver (n = 12) Lung (n = 1)
Study location
Europe 48 (65.8%) 29 (67.4%) 11 (64.7%) 8 (66.7%)
North America 16 (21.9%) 7 (16.3%) 6 (35.3%) 2 (16.7%) 1 (100%)
Asia 5 (6.8%) 4 (9.3%) 1 (8.3%)
Australia 3 (4.1%) 3 (7.0%)
South America 1 (1.4%) 1 (8.3%)
Study design
Prospective observational 26 (35.6) 13 (30.2%) 9 (53.0%) 4 (33.3%)
Cross-sectional 20 (27.4) 13 (30.2%) 4 (23.5%) 3 (25.0%)
Retrospective observational 23 (31.5) 13 (30.2%) 4 (23.5%) 5 (41.7%) 1 (100%)
Case-control 3 (4.1) 3 (7.0%)
Other 1 (1.4) 1 (2.3%)
Sample size
Mean 936 1465 152 227 34
Median 185 231 115 175
Range 34-41705 40-41705 59-381 59-465
Race/ethnicity (mean prevalence in included studies)
Caucasian/White 81.00% 82.64% 79.70% 78.05%
African descent/Black 16.88% 19.86% 24.10% 5.20%
Hispanic/Latinos 1.40% 0.00 2.00% 1.50%
Native American/American Indian, y 0.25% 0.00 0.00 0.50%
Asian/Pacific Islanders 0.50% 0.00 0.00 1.00%
Mean % male sex 67.16% 62.92% 78.42% 68.10% 64.70%
Mean age at transplantation, y 48.50 47.09 50.07 52.83 53.90
SD 11.29 11.66 11.09 10.42 6.67
Range 13-84 13-84 13-83 17-76
Time posttransplant, y
Mean 5.96 5.42 5.94 8.80
SD 3.15 3.02 3.78 2.43
Median 6.74 6.00 7.78
Prevalence of posttransplant smoking
Mean 24.27% 23.84% 25.33% 25.27% 14.7%
SD 13.01 14.44 12.60 8.36
Median 22.20% 22.00% 23.30% 21.24%
Range 1.00-73.00% 1.00-73.00% 9.20-52.00% 16.50-37.93%
IQR, Interquartile range.
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Average effect size estimates could be calculated for 4 out-
comes (Table 3, Figure 7). Across 9 studies, our meta-analysis
showed that the odds of having cardiovascular disease (ie,
new onset disease not present at time of transplantation) were
1.41 times higher than that of nonsmokers (OR, 1.41; 95%
CI, 1.02-1.95; P = 0.036). Based on 6 studies, the odds ratio
for the association between posttransplant smoking and
nonskin malignancies was 2.58 (95% CI, 1.26-5.29;
P = 0.01). The pooled results from 5 and 8 studies showed
a statistically significant association of posttransplant smoking
with patient survival time (OR, 0.59; 95% CI, 0.44-0.79;
P < 0.001) and patient mortality (OR, 1.74; 95% CI, 1.21-
2.48; P = 0.003), respectively.
Assessment of heterogeneity of study effect sizes for outcomes
yields a low I2 value of 38.77% for cardiovascular disease,
moderate I2 value of 50.59% for patient survival time, and high
I2 values of 73.68%and 83.38% for nonskinmalignancies and
patient mortality, respectively (Table 3). Except for 1 study on
nonskin malignancies and 1 study on patient mortality, the di-
rections of the associations across studies were consistent.
DISCUSSION
This systematic review andmeta-analysis comprehensively
summarized the state of the art on correlates of pos-transplant
smoking for the first time. It is also the first investigation that
synthesized study findings on the association of posttransplant
smoking with various clinical outcomes in single adult lung,
heart, liver, and kidney transplant patients. This is useful given
the continued challenge to identify modifiable risk factors to
improve posttransplant outcomes. The results of this meta-
analysis may inform transplant clinicians which patients are
more likely to smoke posttransplant and provide some recom-
mendations for future research in this area.
Surprisingly enough, of the 90 correlates abstracted from
the included papers, we could only calculate pooled effect sizes
for 6 of them.More specifically, we revealed thatmale patients,
younger patients, and patients with a lower BMI were more
likely to be smokers. Hypertension, diabetes mellitus, and a
history of cardiovascular disease were not significantly associ-
ated with posttransplant smoking. However, it is important to
be cautious about drawing conclusions for hypertension and
FIGURE 2. Quality assessment.
FIGURE 3. Socioeconomic-related correlates of posttransplant smoking assessed by 1 to 4 studies.
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diabetes, because the directions of the ORs were inconsistent
across the studies, in addition to high I2 values.
The finding that male patients are more likely to smoke
posttransplant is in line with the World Health Organization
findings showing that men smoke at 5 times the rate of
women (the average rates are 36% and 7%, respectively).56
Globally, however, the gap between men's and women's
smoking rates is becoming smaller. As society became more
tolerant of women who smoke and women's economic re-
sources are increasing, the tobacco industry has been targeting
women through advertisements promoting cigarettes as a
symbol of freedom, emancipation, beauty, and prestige.57,58
So also in transplantation, despite men being more prone to
posttransplant smoking, the rise of smoking among women
needs to be carefully followed.
From our results, it also appeared that older patients were
less likely to smoke than younger patients. A hypothesis
might be that older transplant patients experience more
health problems, including smoking-related illnesses, and
therefore are more likely to stop smoking, yet this merits fur-
ther investigation. Another possibility is that older patients
already died because of smoking-related illnesses and were
subsequently not included in the analyses (ie, survival bias).
For BMI, we found that patients with a higher BMI were
significantly less likely to smoke. On the one hand, this is
not surprising because smokers tend to be leaner than non-
smokers and concerns over weight gain are often a reason
why individuals are reluctant to stop smoking.59,60 On the
other hand, one would expect that unhealthy behaviors,
such as smoking, unhealthy eating, and physical inactivity,
go hand in hand. Also, in the general population, the asso-
ciation between BMI and smoking is complex and not
completely understood, and published studies yielded con-
flicting results.61 More studies are needed to explore possi-
ble causal mechanisms.
Hypertension was not significantly associated with post-
transplant smoking. This should come as no surprise because
although smoking can cause acute blood pressure elevation
through the stimulation of the sympathetic nervous system,62
chronic smoking has not been conclusively shown to cause
high blood pressure in the general population.63 The lack of
an association between diabetes mellitus and posttransplant
smoking, on the other hand, contradicts evidence in other
populations, showing that smokers are 30% to 40% more
likely to develop type 2 diabetes than nonsmokers.64 It might
be that an association in this meta-analysis was not found be-
cause intensity and duration of smoking (including pretrans-
plant smoking) were not taken into account. As indicated
earlier, it must also be noted that there was a significant de-
gree of heterogeneity among the studies for hypertension
and diabetes, making it difficult to draw any firm conclu-
sions. When comparing these different studies, differences
can be observed, with a wide variety between study designs
used, smoking definitions, and smoking assessment methods,
possibly explaining the observed heterogeneity. For 3 of the
7 studies on diabetes, it was also not clear whether diabetes
was already present at time of transplantation or newly de-
veloped after transplantation.
Having a history of cardiovascular disease was also not
significantly associated with posttransplant smoking. In con-
trast to hypertension and diabetes, there was no heterogene-
ity among the studies. The lack of a significant association is
difficult to explain. One would assume that patients who
have a history of cardiovascular disease are probably more
likely to be the ones who smoked pretransplant, and 3 studies
included in this review showed that pretransplant smoking
was associated with posttransplant smoking (Figure 4). On
the other hand, it is possible that having a history of car-
diovascular disease is a good motivator to maintain smoking
abstinence. Additional research examining the association
between having a history of cardiovascular disease and
posttransplant smoking is needed.
For the remaining 89 correlates, no effect sizes could be
calculated. Most of these factors were investigated only once
or twice and focused largely on condition-related factors,
whereas healthcare team and system-related factors were
not studied at all. Yet, smoking is a behavioral process
strongly influenced by the environment in which the patient
lives, including the healthcare practices and systems. Thus,
from a behavioral perspective, healthcare team and system-
related factors should be studied more. The general paucity
of studies examining relevant factors is probably due to a
lack of theoretical underpinnings in the included studies.
Nevertheless, theoretical or conceptual models, like “the In-
tegrated Model of Behavioral Prediction of Fishbein”65 or
“the conceptual framework of the International Tobacco
Control Policy Evaluation Project”66 are valuable in develop-
ing more targeted research questions, in identifying variables
to study, and in interpreting research results.
Of the 24 outcomes abstracted from the included papers,
we could only calculate pooled effect sizes for 4 of them, that
is, cardiovascular disease, nonskin malignancies, patient sur-
vival time, and patient mortality. Our results suggest that
posttransplant smoking is statistically significantly associated
with all 4 outcomes, which is in line with the wide acknowl-
edgment that cigarette smoking is a major risk factor for car-
diovascular disease, cancer, and mortality in the general
population. However, given that smoking globally contrib-
utes to the burden of over 200 diseases, it is remarkable that
few studies (ie, less than 5 studies) explored the effects of
posttransplant smoking on other outcomes, such as graft
loss, stroke, pulmonary diseases, kidney function, osteoporo-
sis, skin problems, and so on. On the other hand, the fact that
73 studies examined correlates/outcomes of posttransplant
FIGURE 4. Patient-related correlates of posttransplant smoking
assessed by 1 to 4 studies.
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smoking indicates that not only pretransplant smoking but
also smoking after transplantation is increasingly recognized
as being important. For a long time, it was assumed that
transplant patients did not smoke after having received the
precious gift of life. However, we should not forget that
smoking is an addiction, hence relapse after transplantation
is always possible.67 Smoking relapse after smoke-free pe-
riods is not typical for transplant patients, but reflects the cy-
clic process of smoking-quitting relapse also observed in the
general population.
Apart from the fact that few pooled effect sizes could be
calculated for both correlates and outcomes, despite the mul-
titude of factors having been explored, some results from the
quality assessment also merit some further reflection. First,
most studies did not provide a definition of smoking, and
for those that did, the definition was not consistent. For ex-
ample, some defined smoking as “smoking 7 or more ciga-
rettes per week,”40 while others simply defined it as current
smoking, regardless of the intensity or duration of smoking.68
Future research should specify the type and “dose” of smoking
over a specific time period (eg, posttransplant or lifetime).
Second, 47 studies (64.4%) did not use a prospective observa-
tional design, hence conclusions cannot bemade about causal-
ity. Third, most studies used self-reporting with its inherent
limitations to determine the prevalence of smoking, with only
a few using biological measures. Some of the inconsistent cor-
relations may be attributed to the use of these different
smoking definitions and measurements. Fourth, although
there are some articles on smoking before lung transplan-
tation, there was only 1 article on correlates or outcomes
of posttransplant smoking in lung transplant patients.29
Although relapse numbers are lower for lung transplant pa-
tients, probably reflecting the strict nonsmoking policy and
regular assessment of a patient's smoking status pretransplant
and posttransplant, they do not equal zero. More specifically,
a recent study of Ruttens and colleagues69 demonstrated that
FIGURE 5. Condition-related correlates of posttransplant smoking assessed by 1 to 4 studies.
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12% of lung transplant patients resumed smoking post-
transplant. Thus, we believe that more studies are needed
to better understand the correlates and outcomes of post-
transplant smoking, especially in this vulnerable transplant
patient group. Fifth, there were studies that only permitted
the effect size estimate to be approximated from less than op-
timal statistical information (eg, only the sample size, infor-
mation on the direction of the association, and a P value
less than or greater than a specified value), leading to less pre-
cise estimates of the effect sizes. Moreover, some studies
could not be included because the data reported did not per-
mit the calculation of an effect size, probably causing some
bias in our review. Although some authors were contacted
in case of missing data, we did not receive the information
needed to calculate the effect sizes.
This systematic review andmeta-analysis might have some
methodological shortcomings aswell. First, despite the exten-
sive and rigorous systematic review process used, it is possi-
ble that relevant papers were missed, bearing in mind that
searching for literature is not an exact science. Second, al-
though we included papers in 7 different languages, we had
to exclude 10 articles due to a foreign language nobody of
the research team could understand. Third, our review is lim-
ited to the occurrence of posttransplant smoking, and we did
not take into account the severity or duration of post-
transplant smoking. Also, by focusing on posttransplant
smoking only, we are aware that we did not look at total life-
time exposure to cigarette smoke (ie, both pretransplant and
posttransplant), which might be important when investigat-
ing impact on outcomes. However, most authors do not clearly
distinguish pretransplant versus posttransplant smoking,
making it impossible to run separate analyses according to
the patients' pretransplant smoking history. These studies
were strictly excluded. Moreover, in case that 3 groups were
reported (nonsmokers, past smokers, and current smokers),
we considered past smokers as nonsmokers, although we
did not know whether these patients quit smoking before
or after transplantation.
FIGURE 6. Treatment-related correlates of posttransplant smoking assessed by 1 to 4 studies.
TABLE 3.
Estimated pooled effect sizes as OR generated under a random effects model
Factor
No.
studies OR
95% CI for the OR Heterogeneity test
τ2 I2 (%)
Classic
fail-safe N
Lower
limit
Upper
limit Q statistic P
Socioeconomic-related
Male sex26-39 14 1.33 1.12 1.57 17.20 0.19 0.02 24.42 64
Older age25-31,33,34,36-39 13 0.48 0.38 0.62 42.18 <0.001 0.11 71.55 375
Condition-related
Body mass index26,27,30,31,36,38,39 7 0.68 0.52 0.89 12.04 0.06 0.06 50.15 23
Hypertension/being treated with antihypertensive drugs27,28,31,36,39-41 7 1.16 0.77 1.75 22.17 0.001 0.19 72.94 —
Diabetes mellitus27,28,30,31,39-41 7 0. 52 0.15 1.78 145.59 <0.001 2.52 97.56 —
History of cardiovascular disease26,28,30,31,39 5 0.92 0.77 1.09 0.97 0.92 0 0 —
Outcome
Cardiovascular disease36,38,40,42-49 11 1.41 1.02 1.95 16.33 0.09 0.10 38.77 8
Nonskin malignancies26,40,50-53 6 2.58 1.26 5.29 18.995 0.002 0.55 73.68 35
Patient survival time24,26,37,50,54 5 0.59 0.44 0.79 8.095 0.088 0.05 50.59 32
Patient mortality26,28-31,50,54,55 8 1.74 1.21 2.48 42.107 <0.001 0.17 83.38 80
T2, Tau-squared, the variance of the true effect sizes; I2, I-squared, the percentage of variations across studies due to heterogeneity rather than chance.
2260 Transplantation ■ November 2016 ■ Volume 100 ■ Number 11 www.transplantjournal.com
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Implications for Clinical Practice
Despite the limitations of this review, it seems reasonable
to conclude that abstinence from cigarette smoking should
be strongly encouraged after transplantation, taking into ac-
count the association with cardiovascular disease, nonskin
malignancies, a shorter patient survival time, and mortality.
Transplant teams have a key role to play in this important
area of prevention. They should be encouraged to focus on
smoking abstinence as a central theme to discuss with the pa-
tient at least at the yearly follow-up check-up. In patients with
higher odds for smoking posttransplant (ie,male patients, youn-
ger patients, patients with a lower BMI), smoking status may
need to be assessed more frequently (every 1 to 3 months).9
Smoking status can be assessed by self-report and/or bio-
logical measures (eg, cotinine measures derived from saliva,
urine, and blood or exhaled carbon monoxide). Although co-
tinine measurements are more objective methods and preferred
over self-reported smoking exposure to assess relation of
smoking with outcomes in epidemiological studies,30 self-report
is probably the most accessible and cost-effective method to
implement in daily clinical practice. Moreover, it has been
shown in nontransplant populations that self-reporting of
smoking can be a valid measurement method, when used
under nonthreatening and open circumstances between
healthcare providers and their patients.70 At the same time,
onemust be aware that some patientsmay not admit smoking,
because smoking after transplantation remains an ethical is-
sue, and it might be considered ethically justified to deny active
smokers a second transplant. Therefore, self-report screening
tools must be validated in transplant populations, and where
possible, combined with cotinine measurements.71
Both the inpatient and the outpatient setting provide an
opportunity to promote smoking cessation to active smokers
and to encourage continued smoking cessation to past and
never smokers. It is important for transplant clinicians to
assess patients' motivation to quit smoking or continue
smoking cessation and to realize that many patients often
make repeated attempts to stop before succeeding in break-
ing their habit. If motivated patients have difficulties to stop
smoking, they can be referred to community smoking cessa-
tion services for more intensive behavioral support.
Further, the Institute of Medicine recommends including
the behavioral assessment and interventions in the electronic
health record, because this has great potential to improve
quality, coordination, safety, health outcomes, and overall ef-
ficiency in healthcare.72
Implications for Future Research
The findings of the current systematic review and meta-
analysis also reveal several important implications for future
research. First, it is important to emphasize the importance of
good and complete reporting. For example, authors should
better define smoking, and report important smoking details,
such as smoking intensity, duration, and number of pack-
years. We also recommend to do separate analyses for pre-
transplant and posttransplant smoking because correlates
and outcomes might be different. Authors also need to report
sufficient information to allow calculation of effect sizes. At
FIGURE 7. Forest plot of pooled effect size estimates for correlates/
outcomes investigated ≥ 5 times.
FIGURE 8. Outcomes of posttransplant smoking assessed by 1 to 4 studies.
© 2016 Wolters Kluwer Duerinckx et al 2261
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
aminimum, they need to report the sample size, exactP value,
and information on the direction of the association. In addi-
tion, future research needs to pay attention to several issues
related to the research methodology. For example, studies
should be guided by theoretical models to examine the mech-
anism of how pretransplant and posttransplant factors in-
fluence posttransplant smoking and how posttransplant
smoking, in turn, may affect outcomes. That way, the rela-
tionship of posttransplant smoking with more targeted fac-
tors at the patient level, healthcare system–related factors
(eg, higher tobacco taxes, antismoking education, bans on
tobacco advertising and promotion, policies designed to
prevent smoking in public spaces or workplaces), quality
of life, and economic outcomes could be explored more.
Furthermore, future studies should also use a prospective
study design whenever possible to establish a meaningful
causal relationship between posttransplant smoking and
its correlates and outcomes. Interventions could then be tai-
lored to those at highest risk for smoking posttransplant.
Third, given the paucity of data, more studies are needed
on correlates and outcomes of posttransplant smoking in
lung transplant patients. Fourth, although not the scope
of the current review, it would also be helpful to evaluate
possible additional risks of electronic cigarette smoking,
secondhand smoking, and smokeless tobacco in the trans-
plant population. And fifth, future studies should examine
whether smoking withdrawal or cessation after solid organ
transplantation has a protective effect against the develop-
ment of cardiovascular disease.
In conclusion, posttransplant smoking is associated with car-
diovascular disease, nonskinmalignancies, a shorter patient sur-
vival time, and mortality. The association of posttransplant
smoking with other outcomes (clinical, economic, and quality
of life outcomes) remains to be evaluated. Male patients, youn-
ger patients, and patientswith a lower BMI aremore likely to be
smokers. Transplant teams play an important role in routinely
assessing patients' smoking status during transplant follow-up
by using self-report and/or cotininemeasurements, assessing pa-
tients' motivation to quit smoking, promoting smoking cessa-
tion, and referring motivated patients to community smoking
cessation services when necessary.
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